Biblio
The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities. Transplant Cell Ther. 2024.
A day 14 endpoint for acute GVHD clinical trials. Transplant Cell Ther. 2024.
Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation. Blood Adv. 2021.
Evaluation of elafin as a prognostic biomarker in acute graft-versus-host disease. Transplant Cell Ther. 2021.
Indole derivatives, microbiome and graft versus host disease. Curr Opin Immunol. 2021;70:40-47.
. . Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2020.
Autologous Transplantation for Male Germ Cell Tumors: Improved Outcomes over 3 decades. Biol Blood Marrow Transplant. 2019.
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3(23):4034-4042.
International, multi-center standardization of acute graft-versus-host disease clinical data collection: a report from the MAGIC consortium. Biol Blood Marrow Transplant. 2015.